Transmission Many potential routes of BLV transmission exist. Transmission through procedures that transmit blood between animals such as gouge dehorning, vaccination and ear tagging with instruments or needles that are not changed or disinfected between animals is a significant means of BLV spread. Rectal
palpation with common sleeves poses a risk that is increased by inexperience and increased frequency of palpation. Transmission via
colostrum, milk, and
in utero exposure is generally considered to account for a relatively small proportion of infections. Embryo transfer and artificial insemination also account for a small number of new infections if common equipment and/or palpation sleeves are used. While transmission has been documented via blood feeding insects, the significance of this risk is unclear. Transmission relies primarily on the transfer of infected lymphocytes from one animal to the next, and BLV positive animals with
lymphocytosis are more likely to provide a source for infection. Virus particles are difficult to detect and not used for transmission of infection.
Clinical signs In general, BLV causes only a benign
mononucleosis-like disease in
cattle. Only some animals later develop a
B-cell leukemia called enzootic bovine leukosis. Under natural conditions the disease is transmitted mainly by
milk to the calf. The variety of organs where
white blood cells occur explains the many symptoms: enlargement of superficial lymph nodes, a digestive form, a cardiac form, a nervous form, a respiratory form, and others. Lymph node enlargement is often an early clinical sign. An unexpected clinical finding is protrusion of the conjunctival membrane, due to enlargement of retro-ocular lymph nodes. High prevalence of virus was found from testing by USDA. "As part of the 2007 dairy study, bulk tank milk was collected from 534 operations with 30 or more dairy cows and tested with an Enzyme Linked-Immunosorbent Assay (ELISA) for the presence of antibodies against BLV. Results showed that 83.9 percent of U.S. dairy operations were positive for BLV (table 1). The approach is based on a provirus with deletions or mutations in genes required for efficient replication (R3,G4, microRNAs, envelope). The attenuated vaccine effectively protects from BLV infection in endemic regions characterized by a high BLV prevalence. Compared to wild-type infection, the humoral response against BLV antigens is only slightly reduced in vaccinated animals. The proviral loads of the attenuated vaccine remain most frequently undetectable. The attenuated strain is not transmitted from mother to offspring, supporting the safety of the vaccine. This vaccine thus induces a persistent anti-BLV immune response through maintaining a low level of infectivity, while preventing the risk of infection by the wild-type virus. ==Potential infection in humans==